ChatGPT's role in the rapidly evolving hematologic cancer landscape.

Many patients seek accurate, understandable information about their disease and treatment, turning to the internet or messaging providers. This study aims to validate chatbots' ability to deliver accurate information, contributing to the literature on AI's role in cancer care and helping to improve these tools for patients and caregivers. A set of questions about hematologic malignancies was created with input from oncologists and reputable websites and then submitted to ChatGPT 3.

Comparative effectiveness of remote perioperative telemonitoring in cancer surgery: a randomized trial.

This randomized trial compared remote perioperative telemonitoring (RPM) care versus surgeon only care in patients with gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancers (N = 293). The RPM care arm wore a wristband accelerometer and reported symptoms via a mobile application (app) before surgery and at days 7, 14, 30, 60, 90 post-discharge. Triage nurses telephoned patients when data deviated from predetermined thresholds.

An HRQOL Proof-Of-Concept Analysis of the eHealth TOGETHER Intervention for Adolescent and Young Adult Cancer Survivors: A Brief Report.

Background: Adolescent and young adult (AYA) cancer survivors ages 18-39 report elevated stress and poor health-related quality of life (HRQOL), yet few evidence-based stress management interventions exist that meet their specific needs. Our team designed TOGETHER, a 10-week eHealth group-delivered behavioral intervention designed to improve HRQOL via stress management skills training. To date, TOGETHER has been delivered to seven groups of AYAs, and its feasibility and acceptability have been well established.

A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.

Vocimagene amiretrorepvec (Toca 511) is a replicating retroviral vector (RRV) encoding cytosine deaminase that converts 5-fluorocytosine (5-FC) into 5-fluorouracil in the tumor microenvironment. This study investigated the safety and immunomodulatory effects of systemically administered Toca 511 and Toca FC in advanced cancer patients. Eligible subjects received three daily intravenous (i.

Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report.

Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoma that is highly responsive to the purine analog cladribine. A defining feature of classical HCL is the presence of the BRAF V600E mutation, which is almost universally present. The transformation of HCL to an aggressive large B-cell lymphoma is extremely rare.

HER2 Alterations across Solid Tumors: Implications for Comprehensive Testing.

Purpose: ERBB2 (HER2) alterations (e.g., overexpression, amplification, and mutations) are known to drive tumor progression.

XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies.

TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most aggressive and chemotherapy refractory myeloid neoplasms with a median overall survival of less than 6 months. An enormous unmet need exists to develop novel therapeutic strategies and understand resistance mechanisms to suboptimal existing therapies for this disease. In two parallel phase 2 clinical trials that combined eprenetapopt with azacitidine in TP53 mutated MDS/AML, we observed complete remission rates of 40-50% and molecular remission rates of 38%.

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML.

Olutasidenib is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that was recently approved by the US FDA for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring mutant IDH1. In the pivotal Phase II trial of olutasidenib, the median duration of complete response (CR) was 28.1 months.

Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies.

Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Emerging data indicate that prophylactic tocilizumab may reduce CRS, without impacting efficacy. We administered a single dose of tocilizumab prior to the first dose of bispecific antibodies to 119 patients to determine the impact on CRS in a real-world setting including BCMAxCD3- and GPRC5DxCD3-targeted antibodies.

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK).

Purpose: To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and Guardant360 CDx (G360 ctDNA) liquid biopsy for biomarker detection in metastatic nonsquamous non-small cell lung cancer.

Patients And Methods: This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore.

ACR-ARS Practice Parameter for Image-Guided Radiation Therapy (IGRT).

Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and American Radium Society (ARS). Image-guided radiation therapy (IGRT) uses various imaging modalities to maximize the accuracy and precision of radiation treatment delivery.

Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.

Training and Validating a Knowledge-Based Model for Intensity Modulated Proton Therapy of Prostate and Pelvic Lymph Nodes.

Introduction In this work, we aimed to create and assess the performance of a knowledge-based planning (KBP) model for optimizing intensity-modulated proton therapy (IMPT) in the treatment of prostate cancer involving pelvic lymph nodes (LNs). Materials and methods Fifty patients previously treated with IMPT to the prostate/prostate bed, including LNs and optional gross tumor volume (GTV) boost, were used for the training of a KBP model. The model was iteratively refined by replanning a subset of 20 of these patients.

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.

Venetoclax (VEN) plus a hypomethylating agent (HMA) regimen is the standard of care for older adults with acute myeloid leukemia (AML); however, it is associated with significant myelosuppression and complications, potentially limiting its use in those who are very old. We performed a multicenter retrospective analysis of VEN-HMA treatment in octogenarians and nonagenarians to further understand the tolerability, feasibility, dosing considerations, and clinical efficacy in this unique group. Patients with AML aged ≥80 years who received VEN-HMA between March 2015 and April 2022 were reviewed.

Liposarcoma: Novel Approaches to Systemic Therapy and Multidisciplinary Care.

Retroperitoneal well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are rare tumors presenting as bulky abdominal tumors requiring multidisciplinary management in high-volume centers. Surgery is the mainstay of treatment through complete en bloc resection with the goal of achieving macroscopically complete resection, with a single specimen encompassing the tumor and involved contiguous organs. Preoperative radiation therapy is not standard of care and the role of preoperative chemotherapy is under investigation.

Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.

Acral lentiginous melanoma (ALM) is a rare and insufficiently understood subtype of melanoma lacking in effective treatment options. Recent work has demonstrated that the response of ALM to immune checkpoint blockade is inferior to that of cutaneous melanoma (CM). Here we performed bulk genomic and transcriptomic sequencing of tumor tissue from 28 ALM and 5692 CM cases.

Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Purpose: Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy is associated with an inflammatory state that may exacerbate sarcopenia. The relationship among CAR T-cell therapy, sarcopenia, and metabolism is poorly understood.

Correlation of T2-Weighted Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Cone Beam Computed Tomography (CBCT) Radiomic Features for Prostate Cancer.

Radiomics extracted from cone beam computed tomography (CBCT) can be assessed at time points during treatment and may provide an advantage over assessments in a pre-treatment setting using diagnostic images, like magnetic resonance imaging (MRI) or computed tomography (CT), for prostate cancer (pCa) patients receiving radiotherapy (RT). The purpose of this study was to analyze correlations between prostate radiomic features (RFs) derived from T2-weighted (T2w) MRI, CT, and first fraction CBCT for patients receiving RT for pCa. Forty-seven patients were analyzed.

Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States.

Purpose: Although international medical graduates (IMGs) and Puerto Rican Medical Graduates (PRMGs) comprise an integral part of the health care workforce, these individuals, particularly women, frequently face numerous types of discrimination throughout medical training and independent practice. To our knowledge, we conducted the first cross-sectional study to understand the journeys and consequences of migration faced by IMGs and PRMGs in the US oncology workforce.

Methods: We developed a cross-sectional, online survey consisting of 51 multiple choice and open-ended questions that captured demographic information, professional status, period of migration to the United States, location within the United States that participants migrated to, reasons for migration, cultural adaptation, experiences of discrimination during training, and overall professional experiences in the United States.

Structural racism and breast cancer stage at presentation in a South Florida majority-minority population: a retrospective study.

Background: Residential segregation, both economic, racial and ethnic, is a social determinant of health that contributes to disparities in breast cancer outcomes. The objective of this study was to examine the association of economic and racial and ethnic residential segregation, as measured by the Index of Concentration at the Extremes (ICE), with breast cancer stage at presentation.

Methods: In this retrospective two-institution study, we included patients with stage I-IV breast cancer from 2005 to 2017.

Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.

Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is unclear. We compared outcomes in allo-HCT recipients ≥50 years old after HCT from an older MSD (≥50 years) with recipients of younger (≤35 years) HLA-matched unrelated donor (MUD), haploidentical related donor (haplo), and HLA-mismatched unrelated donor (MMUD), grouped based on PTCy or calcineurin-inhibitor (CNI) based GVHD prophylaxis, that were reported to the Center for International Blood and Marrow Transplant Research between 2014 and 2021. The primary end point was overall survival (OS).

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.

Background: LOXO-338 is a novel, orally bioavailable small-molecule inhibitor of Bcl-2, designed to achieve selectivity for Bcl-2 over Bcl-xL, thus avoiding dose-limiting thrombocytopenia associated with Bcl-xL inhibition. This first-in-human, open-label, Phase 1 study investigated LOXO-338 in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell non-Hodgkin lymphoma (NHL) (NCT05024045).

Patients And Methods: Patients with histologically confirmed advanced B-cell malignancies who had received ≥ 2 prior therapies were enrolled in Phase 1 dose escalation (interval 3 + 3 design).

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

Background: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2 Gy versus 79.2 Gy.